Core Viewpoint - *ST Suwu has shown a significant increase in stock price and strong financial performance, indicating potential growth in the pharmaceutical and medical beauty sectors [1][2]. Group 1: Company Overview - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is located at 988 Dongfang Avenue, Wuzhong District, Suzhou, and operates in the pharmaceutical, medical beauty, and investment industries [1]. - The company's pharmaceutical products cover areas such as antiviral/infection control, immune regulation, anti-tumor, digestive system, and cardiovascular fields [1]. - The medical beauty segment holds exclusive agency rights for Korean medical beauty products in China [1]. - The company aims to develop a health industry cluster with a focus on pharmaceutical health and emerging sectors like medical beauty in its 2020-2024 strategic plan [1]. Group 2: Financial Performance - As of September 30, *ST Suwu had 61,600 shareholders, with an average of 11,500 circulating shares per shareholder [2]. - For the period from January to September 2024, *ST Suwu achieved a revenue of 1.647 billion yuan, representing a year-on-year growth of 9.58% [2]. - The net profit attributable to shareholders for the same period was 45.08 million yuan, showing a substantial year-on-year increase of 311.54% [2].

Core Viewpoint - *ST Suwu is facing potential delisting due to significant violations, including continuous financial fraud and misleading disclosures, as indicated by the China Securities Regulatory Commission (CSRC) [1][6] Group 1: Violations and Penalties - The company has been found guilty of failing to disclose the actual controller from 2018 to 2023, misrepresenting Qian Qunshan as the actual controller instead of the true controller [2] - *ST Suwu inflated its operating income, operating costs, and profits from 2020 to 2023, with inflated revenues of 495 million, 468 million, 431 million, and 377 million respectively, accounting for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues [3] - The company failed to disclose significant non-operating fund occupation by related parties, with balances of 127 million, 1.393 billion, 1.543 billion, and 1.693 billion from 2020 to 2023, representing 6.88%, 74.2%, 84.6%, and 96.09% of net assets [4] Group 2: Regulatory Actions - The CSRC plans to impose a fine of 10 million on *ST Suwu and additional fines on key executives, including 15 million on Qian Qunshan, 2 million on Qian Qunying, and 1.5 million on Chen Yi [5] - Qian Qunshan is also facing a 10-year ban from the securities market due to the severity of his actions as the actual controller and chairman [5] - The company acknowledges the potential for mandatory delisting and plans to cooperate with the CSRC while maintaining that its operations are normal as of the announcement date [6]

Core Viewpoint - *ST Suwu has been found guilty of multiple violations, including falsifying financial statements and failing to disclose the actual controlling shareholder, leading to a proposed fine of 10 million yuan and potential delisting from the stock exchange [1][6]. Summary by Sections Violations Identified - The company failed to disclose the actual controlling shareholder, with false records in annual reports from 2018 to 2023, incorrectly naming Qian Qunying as the actual controller instead of Qian Qunshan [2]. - *ST Suwu inflated revenue, costs, and profits through non-commercial trade activities with related companies, resulting in inflated revenues of 495 million yuan, 468 million yuan, 431 million yuan, and 377 million yuan for the years 2020 to 2023, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues respectively [3]. - The company also failed to disclose significant non-operating fund occupations by related parties, with balances of 127 million yuan, 1.393 billion yuan, 1.543 billion yuan, and 1.693 billion yuan from 2020 to 2023, representing 6.88%, 74.2%, 84.6%, and 96.09% of net assets respectively [5]. Proposed Penalties - The China Securities Regulatory Commission (CSRC) proposed a fine of 10 million yuan for *ST Suwu and a 10-year market ban for Qian Qunshan, the actual controller and chairman [6][7]. - Additional fines were proposed for other board members, including 15 million yuan for Qian Qunshan, 2 million yuan for Qian Qunying, and 1.5 million yuan for Chen Yi [7]. Company Status - As of July 11, *ST Suwu's stock price was 2.42 yuan per share, with a total market capitalization of 1.723 billion yuan [10]. - The company has stated it will cooperate with the CSRC and exercise its rights to defend against the proposed penalties [9].

Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company may face major illegal delisting due to inflated revenue, costs, and profits in its annual reports from 2020 to 2023 [2][5][7]. Summary by Relevant Sections Administrative Penalty Notice - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, leading to inflated financial figures [5][7]. - The company is at risk of being delisted under the Shanghai Stock Exchange's rules due to these violations [2][10]. Financial Impact - The inflated revenue figures from 2020 to 2023 were reported as follows: - 2020: 495 million yuan (26.46%) - 2021: 469 million yuan (26.39%) - 2022: 431 million yuan (21.26%) - 2023: 377 million yuan (16.82%) [7]. - The inflated costs were: - 2020: 481 million yuan (37.08%) - 2021: 448 million yuan (35.47%) - 2022: 411 million yuan (28.40%) - 2023: 355 million yuan (20.95%) [7]. - The inflated profit figures were: - 2020: 14.58 million yuan (2.89%) - 2021: 20.27 million yuan (51.65%) - 2022: 19.92 million yuan (26.42%) - 2023: 21.22 million yuan (29.81%) [7]. Company Response and Future Actions - *ST Suwu has issued its first risk warning regarding the potential for major illegal delisting [8]. - If the company receives a formal penalty decision confirming the violations, it will apply for a trading suspension and disclose relevant information [10]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's stock listing within five trading days of the suspension [10]. Recent Financial Performance - For the year 2024, *ST Suwu reported: - Revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year - Net profit attributable to shareholders of 70.48 million yuan, compared to a loss of 71.95 million yuan in 2023 [10][11].

Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company has inflated its operating income, operating costs, and profits from 2020 to 2023, which may lead to a forced delisting due to significant violations [2][10]. Summary by Sections Administrative Penalty Notice - On July 13, *ST Suwu announced it received an administrative penalty notice from the CSRC, which identified false records in its annual reports from 2020 to 2023 [2][10]. - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, resulting in inflated financial figures [7]. Financial Impact - The inflated operating income for the years 2020 to 2023 was reported as follows: 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion, representing 26.46%, 26.39%, 21.26%, and 16.82% of the reported operating income for those years, respectively [9]. - The inflated operating costs for the same years were 4.81 billion, 4.48 billion, 4.11 billion, and 3.55 billion, accounting for 37.08%, 35.47%, 28.40%, and 20.95% of the reported operating costs [9]. - The inflated total profits were 14.58 million, 20.27 million, 19.92 million, and 21.22 million, which constituted 2.89%, 51.65%, 26.42%, and 29.81% of the reported total profits for those years [10]. Regulatory Actions - The CSRC plans to impose a fine of 10 million yuan on *ST Suwu and a total of 20.5 million yuan in fines on its executives [10]. - The company has issued its first risk warning announcement regarding the potential for forced delisting due to significant violations [11][12]. Future Implications - If *ST Suwu receives a formal administrative penalty decision indicating significant violations, it will apply for a trading suspension and disclose relevant information promptly [14]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's listing within five trading days of the suspension [14]. Recent Financial Performance - In 2024, *ST Suwu reported an operating income of 1.599 billion, a year-on-year decrease of 28.64%, with a net profit attributable to shareholders of 70.48 million, compared to a net loss of 71.95 million in 2023 [15].

Core Viewpoint - The article discusses the ongoing regulatory issues faced by *ST Suwu, including the investigation of its chairman by the China Securities Regulatory Commission (CSRC) and the implications for the company's financial health and operations [2][3]. Group 1: Regulatory Issues - The chairman of *ST Suwu, Qian Qunshan, is under investigation by the CSRC, which has issued a notice of investigation. This investigation is focused solely on the chairman and is not expected to significantly impact the company's daily operations [3]. - In February 2024, *ST Suwu received a notice from the CSRC regarding suspected violations of information disclosure laws, which could lead to severe penalties, including potential delisting [3][8]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year, and a net profit attributable to shareholders of 70.48 million yuan [6]. - The company has been issued a non-standard audit opinion due to issues related to the misuse of funds by related parties, with 769 million yuan reported as misappropriated and not returned [6]. Group 3: Business Operations - *ST Suwu operates in the pharmaceutical sector through its subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [4]. - The company aims to develop a dual-driven strategy focusing on both pharmaceutical and medical beauty sectors, leveraging opportunities in the health industry to enhance market competitiveness [6]. Group 4: Legal and Financial Risks - The company faces additional legal challenges, including a lawsuit against its subsidiary's former legal representative for alleged fraud related to export tax rebates, with the first court hearing scheduled for April 2025 [7]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [7].

Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].